http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010280691-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
| filingDate | 2010-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e35e8ea3d0cfe09e50770929cfc1e9be |
| publicationDate | 2010-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010280691-A |
| titleOfInvention | Method for identifying polypeptide antigens associated with diseases associated with abnormal cell proliferation and compositions effective for the treatment of such diseases |
| abstract | The present invention provides methods and compositions for the development of effective cancer therapies using mitotic inhibitors that have limited general toxicity to normal non-cancerous cells and tissues. A cytotoxic compound obtained by conjugating a cell binding agent (eg, antibody) to an anti-mitotic compound (eg, maytansinoid) is used. Furthermore, since it has substantially no ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC), the therapeutic effect is due to ADCC and / or CDC. It provides antibodies that are sure to be mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than indirect cell killing. Furthermore, this antibody has the ability to distinguish polypeptide antigens that are expressed more in proliferating cancer cells than in proliferating non-cancerous cells. [Selection figure] None |
| priorityDate | 2001-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1124.